Evidence map›Paper›PMID 36399284›Full record

ArticleArchives of pharmacal research2022

New tricyclic systems as photosensitizers towards triple negative breast cancer cells.

Marilia Barreca, Angela Maria Ingarra, Maria Valeria Raimondi, Virginia Spanò, Antonio Palumbo Piccionello, Michele De Franco, Luca Menilli, Valentina Gandin, Giorgia Miolo, Paola Barraja and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of pharmacal research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Molecules (Basel, Switzerland) · 2024
    Review
  3. Thiazole, Isatin and Phthalimide Derivatives TestedCurrent medicinal chemistry · 2024
    Review
  4. Review
  5. Article
  6. The Antitumor Activity of Piplartine: A Review.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  7. 2-Alkyl-Substituted-4-Amino-Thieno[2,3-Molecules (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Recent Advances in the Green Synthesis of ActivePharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Article
  11. Article
  12. Novel 2-alkythio-4-chloro-International journal of molecular sciences · 2023
    Article
  13. Heterocyclic Compounds as Synthetic Tyrosinase Inhibitors: Recent Advances.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Antitumor Activity of Bioactive Compounds fromPharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marilia BarrecaDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Angela Maria IngarraDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Maria Valeria RaimondiDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Virginia SpanòDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy. virginia.spano@unipa.it.
Antonio Palumbo PiccionelloDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Michele De FrancoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padua, Italy.
Luca MenilliDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padua, Italy.
Valentina GandinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padua, Italy.
Giorgia MioloDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131, Padua, Italy. giorgia.miolo@unipd.it.
Paola BarrajaDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
Alessandra MontalbanoDepartment of Biological, Chemical, and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123, Palermo, Italy.
University of Palermo · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nineteen pyrrolo[1,2-h][1,7]naphthyridinones and pyrido[2,3-c]pyrrolo[1,2-a]azepinones were synthesized as new tricyclic systems in which the pyridine ring is annelated to the 6,7-dihydroindolizin-8(5H)-one and 5,6,7,8-tetrahydro-9H-pyrrole[1,2-a]azepine-9-one moieties to obtain potential photosensitizing agents. They were tested for their photoantiproliferative activity on a triple-negative breast cancer cell line, MDA-MB-231, in the dark and under UVA light (2.0 J/cm

Indexed as

Photosensitizing AgentsTriple Negative Breast NeoplasmsApoptosisCell DeathHumansReactive Oxygen SpeciesPhotosensitizing AgentsReactive Oxygen SpeciesMDA-MB-231Photosensitizing agentsPhototoxic activityPyrido[2,3-c]pyrrolo[1,2-a]azepinonePyrrolo[1,2-h][1,7]naphthyridinoneTriple-negative breast cancer

Identifiers

PMID36399284
PMCPMC9701179
OpenAlexW4309288330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.